Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study
Authors:
- Elvire Pons-TostivintEPElvire Pons-Tostivint
- Remy EzzedineRERemy Ezzedine
- Thomas GoronflotTGThomas Goronflot
- Perrine CrequitPCPerrine Crequit
- Thierry ChatellierTCThierry Chatellier
- Judith RaimbourgJRJudith Raimbourg
- Jaafar BennounaJBJaafar Bennouna
- Etienne Giroux LeprieurELEtienne Giroux Leprieur
- Marie PorteMPMarie Porte
Open Access
- 9 July 2024
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 194
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 studyThe Lancet, 2023
- Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancerInvestigational New Drugs, 2022
- Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIANESMO Open, 2022
- Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆Annals of Oncology, 2021
- Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trialThe Lancet Oncology, 2020
- Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trialThe Lancet Oncology, 2020
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trialThe Lancet, 2019
- Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancerLung Cancer, 2017
- Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective AnalysisClinical Lung Cancer, 2015
- Small cell lung cancer: Where do we go from here?Cancer, 2014